Antiphospholipid Syndrome: Therapeutic Challenges

Am J Ther. 2020 May/Jun;27(3):e328-e330. doi: 10.1097/MJT.0000000000000995.

Authors

Hussam Alhasson¹, Abdullah Abdullah¹, Amr Salama¹, Richard Alweis^{1

2

3}, Timothy Woodlock^{4

5}

Affiliations

¹ Department of Medicine, Rochester Regional Health-Unity Hospital, Rochester, NY.
² Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY.
³ School of Health Sciences, Rochester Institute of Technology, Rochester, NY.
⁴ Department of Oncology, Rochester Regional Health-Unity Hospital, Rochester, NY.
⁵ Department of Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY.

PMID: 31135387
DOI: 10.1097/MJT.0000000000000995

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Angiography
Antibodies, Anticardiolipin / blood*
Antibodies, Anticardiolipin / immunology
Anticoagulants / administration & dosage*
Anticoagulants / adverse effects
Antiphospholipid Syndrome / blood
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / diagnosis*
Antiphospholipid Syndrome / immunology
Blood Transfusion
Female
Gastrointestinal Hemorrhage / chemically induced
Gastrointestinal Hemorrhage / therapy
Humans
Mesenteric Ischemia / diagnosis
Mesenteric Ischemia / immunology
Mesenteric Ischemia / therapy*
Middle Aged
Recurrence
Thrombectomy
Treatment Outcome
Venous Thrombosis / diagnosis
Venous Thrombosis / immunology
Venous Thrombosis / therapy*
Warfarin / administration & dosage
Warfarin / adverse effects

Substances

Antibodies, Anticardiolipin
Anticoagulants
Warfarin